PricewaterhouseCoopers (PwC) released the results of a survey that analyzed the relationship of life-science companies with the US Food and Drug Administration and their views of the agency.
PricewaterhouseCoopers (PwC) released the results of a survey that analyzed the relationship of life-science companies with the US Food and Drug Administration and industry's views of the agency. The survey also examined consumers’ perception of product safety and effectiveness of pharmaceuticals and medical devices. A key finding from the 2010 survey was that was that life-sciences companies feel communication with FDA has improved steadily since passage of the FDA Modernization Act of 1997, but cited concerns over the level of the agency’s resources required to keep pace with the agency’s functions.
Specifically, the survey found that:
The survey respondents also had mixed opinions about the effectiveness of user fees for prescription drugs. Almost half (46%) said that user fees have not accelerated the review process, and 30% thought the fees were excessive compared with the time FDA spends on review. Forty-eight percent of companies felt that FDA has not been clear about the intended purpose of user fees nor transparent about the way they are applied.
Despite some reservations from life-science companies, the public as a whole is generally satisfied with the agency’s performance although consumers cite ground for improvement. The survey found that 93% of US consumers are confident about the safety and effectiveness of drugs and medical devices approved for use in the US, and two-thirds agree that the US has the highest standards in the world for drug safety and effectiveness. Seventy-two percent of respondents have confidence that the FDA monitors product safety after products are approved and sold to the public.
However, although approximately one-half (51%) of respondents think FDA does a good job, more than one-third (36%) of US consumers say they have lost confidence in the FDA over the past two years as a result of high-profile safety concerns and product recalls. Also, more than half (56%) said they would be willing to use drugs and devices approved outside the US before they are approved by FDA.
In addition to FDA’s role in drug safety, consumers also were interested in knowing about a company that produces a given drug or device. Nearly all respondents (97%) said that the reputation of the company that makes a drug or device is “important” to them, and 49% said it was “very important.”
The 2010 survey was distributed electronically to potential respondents in the life-sciences industry, including companies that develop biologic, drug, and medical-device products. Findings represent respondents from 50 companies. The survey was completed in the summer of 2010. The PwC consumer survey was conducted online among a cross-section of 1000 US adults and was completed in October 2010.